Search - tctmd.com

Displaying 1 - 20 of 58

Sort: Relevancy | Date

Presentation ESC 2025

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

August 30, 2025

Presentation Controversies and Advances 2025

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Presenter: Peter P. Toth

January 30, 2025

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation ACC 2024

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Presenter: Steven E. Nissen

April 08, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

Presentation TCT 2023

TCT 461: Suboptimal Lipid Lowering Treatment After Complex PCI in Contemporary Practice

Presenter: Denise Peeters

October 25, 2023

Presentation TCT 2023

TCT 271: Characterizing pathophysiological patterns of coronary artery disease among Individuals with Elevated Lipoprotein(a).

Presenter: Mick Renkens

October 25, 2023

Presentation TCT 2023

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

Presenter: Jung-Hee Lee

October 25, 2023

Presentation TCT 2023

TCT 160: Comparative Effectiveness of Moderate-intensity Statin with Ezetimibe Combination Therapy Versus High-intensity Statin Monotherapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study

Presenter: Ji-Yong Jang

October 25, 2023

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing PCI

Presentation TCT 2023

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing Percutaneous Coronary Intervention: A Nationwide, Retrospective, Population-based Study Using National Health Insurance Data…

Presenter: Young-Hoon Seo

October 25, 2023

Presentation TCT 2023

TCT 628: The Impact of Long-term Exposure to Air Pollution on Plaque Characteristics Assessed by Intravascular Optical Coherence Tomography

Presenter: Juhwan Lee

October 25, 2023

Presentation TCT 2023

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

Presenter: Karlis Trusinskis

October 25, 2023

Presentation TCT 2023

TCT 379: Impact of the Residual Lipid Burden on the Clinical and Angiographic Outcomes After Percutaneous Coronary Intervention

Presenter: Woohyeun Kim

October 25, 2023

Advertisement

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Safety and Pharmacodynamic Effects of VERVE-101

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

TCT 461: Suboptimal Lipid Lowering Treatment After Complex PCI in Contemporary Practice

TCT 271: Characterizing pathophysiological patterns of coronary artery disease among Individuals with Elevated Lipoprotein(a).

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

TCT 160: Comparative Effectiveness of Moderate-intensity Statin with Ezetimibe Combination Therapy Versus High-intensity Statin Monotherapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study

TCT 50: Statin and Ezetimibe Combination Therapy Versus Statin Monotherapy for Cardiovascular Outcomes Among Patients Undergoing Percutaneous Coronary Intervention: A Nationwide, Retrospective, Population-based Study Using National Health Insurance Data…

TCT 628: The Impact of Long-term Exposure to Air Pollution on Plaque Characteristics Assessed by Intravascular Optical Coherence Tomography

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

TCT 379: Impact of the Residual Lipid Burden on the Clinical and Angiographic Outcomes After Percutaneous Coronary Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content